Shared on 21 Oct 25

Fair value Increased 1.12%

Analysts have raised their price target for ResMed to $295 from $292, citing improved profit margin expectations and better anticipated gross margin expansion. This comes despite concerns over slower market growth dynamics.

Read more

0 votesShare

Shared on 04 Aug 25

Fair value Increased 8.53%

The upward revision in ResMed’s consensus price target reflects a modest increase in its future P/E multiple amid stable profit margins, resulting in a new fair value estimate of $289.71. What's in the News Repurchased 419,000 shares for $100 million, completing 9,210,000 shares repurchased ($863.38 million) under the long-term buyback program.

Read more

1 votesShare

Shared on 07 May 25

Fair value Increased 2.75%

Read more

0 votesShare

Shared on 30 Apr 25

Fair value Decreased 3.39%

AnalystConsensusTarget made no meaningful changes to valuation assumptions.

Read more

0 votesShare

Shared on 23 Apr 25

Fair value Increased 0.21%

AnalystConsensusTarget made no meaningful changes to valuation assumptions.

Read more

0 votesShare

Shared on 16 Apr 25

Fair value Decreased 1.21%

AnalystConsensusTarget made no meaningful changes to valuation assumptions.

Read more

0 votesShare

Shared on 09 Apr 25

Fair value Decreased 0.25%

AnalystConsensusTarget made no meaningful changes to valuation assumptions.

Read more

0 votesShare

Shared on 02 Apr 25

Fair value Increased 2.09%

AnalystConsensusTarget made no meaningful changes to valuation assumptions.

Read more

0 votesShare

Shared on 26 Mar 25

Fair value Increased 0.26%

AnalystConsensusTarget made no meaningful changes to valuation assumptions.

Read more

0 votesShare

Shared on 19 Mar 25

AnalystConsensusTarget made no meaningful changes to valuation assumptions.

Read more

0 votesShare

Shared on 10 Mar 25

Fair value Decreased 0.55%

AnalystConsensusTarget made no meaningful changes to valuation assumptions.

Read more

0 votesShare